KURA ONCOLOGY INC (KURA) Stock News

USA - Nasdaq - NASDAQ:KURA - US50127T1097 - Common Stock

11.15 USD

-0.29 (-2.53%)

Last: 12/2/2025, 10:12:03 AM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

KURA Latest News, Press Relases and Analysis

All

Press Releases

2 hours ago - By: Kura Oncology, Inc.

First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin

7 days ago - By: Kura Oncology, Inc.

KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML)

18 days ago - By: Benzinga

Kura Scores A Big Win As FDA Approves Its New Leukemia Pill

18 days ago - By: Stocktwits

Kura Oncology Stock Ignites Retail Frenzy After FDA Clears First Daily Pill For Relapsed Leukemia Patients

19 days ago - By: Kura Oncology, Inc.

Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI™ (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia

a month ago - By: Benzinga - Mentions: SEE HRMY FOLD UPST ...

Earnings Scheduled For November 4, 2025

a month ago - By: Stocktwits - Mentions: ITOT URTY

News Image

KURA Stock Rises Pre-Market After Receiving Milestone Payment Related To Cancer Drug Development Agreement

20 days ago - By: Kura Oncology, Inc.

Kura Oncology to Participate in Upcoming Investor Conference

25 days ago - By: Kura Oncology, Inc.

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

a month ago - By: Kura Oncology, Inc.

Kura Oncology Reports Third Quarter 2025 Financial Results

a month ago - By: Kura Oncology, Inc.

Kura Oncology Receives Second $30 Million Development Milestone Payment in AML Menin Inhibitor Program With Kyowa Kirin

a month ago - By: Kura Oncology, Inc.

Kura Oncology and Kyowa Kirin Announce Presentations of Ziftomenib Ven/Aza Combination Data in Frontline and Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia at 2025 ASH Annual Meeting

4 months ago - By: The Motley Fool

Kura (KURA) Revenue Drops 61%

a month ago - By: Kura Oncology, Inc.

Kura Oncology to Report Third Quarter 2025 Financial Results

a month ago - By: Kura Oncology, Inc.

Kura Oncology Receives $30 Million Development Milestone Payment in Ziftomenib AML Program with Kyowa Kirin

2 months ago - By: Kura Oncology, Inc.

Kura Oncology Announces Preliminary Data from Its Farnesyl Transferase Inhibitor (FTI) Programs at the 2025 European Society for Medical Oncology (ESMO) Congress

2 months ago - By: Kura Oncology, Inc.

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: Kura Oncology, Inc.

Kura Oncology and Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition of NPM1 and FLT3 Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

2 months ago - By: Kura Oncology, Inc.

Kura Oncology and Kyowa Kirin Announce First Patient Dosed in Pivotal Phase 3 KOMET-017 Trial of Ziftomenib for Frontline Acute Myeloid Leukemia (AML)

2 months ago - By: Kura Oncology, Inc.

Kura Oncology and Kyowa Kirin Announce Publication of Pivotal Ziftomenib Data in Relapsed/Refractory NPM1-Mutated AML in the Journal of Clinical Oncology

2 months ago - By: Kura Oncology, Inc.

Kura Oncology to Participate in Upcoming Investor Conference

3 months ago - By: Kura Oncology, Inc.

Kura Oncology Highlights Preclinical Data Demonstrating Potential of Farnesyl Transferase Inhibitors to Overcome Drug Resistance in Combination with Key Targeted Therapies Across Multiple Tumor Types

3 months ago - By: Kura Oncology, Inc.

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Kura Oncology, Inc.

Kura Oncology to Host Virtual Investor and Analyst Events on Farnesyl Transferase Inhibitor Program

3 months ago - By: Kura Oncology, Inc.

Kura Oncology to Participate in Three Upcoming Investor Conferences

4 months ago - By: Zacks Investment Research - Mentions: ROIV

Kura Oncology (KURA) Reports Q2 Loss, Lags Revenue Estimates

4 months ago - By: Kura Oncology, Inc.

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: Kura Oncology, Inc.

Kura Oncology to Report Second Quarter 2025 Financial Results